GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectorite Biomedical Inc (ROCO:4170) » Definitions » EV-to-Revenue

Vectorite Biomedical (ROCO:4170) EV-to-Revenue : 6.66 (As of Jun. 03, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Vectorite Biomedical EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vectorite Biomedical's enterprise value is NT$384.54 Mil. Vectorite Biomedical's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$57.77 Mil. Therefore, Vectorite Biomedical's EV-to-Revenue for today is 6.66.

The historical rank and industry rank for Vectorite Biomedical's EV-to-Revenue or its related term are showing as below:

ROCO:4170' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.61   Med: 9.09   Max: 62.9
Current: 6.66

During the past 13 years, the highest EV-to-Revenue of Vectorite Biomedical was 62.90. The lowest was 2.61. And the median was 9.09.

ROCO:4170's EV-to-Revenue is ranked better than
53.46% of 997 companies
in the Biotechnology industry
Industry Median: 7.39 vs ROCO:4170: 6.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-03), Vectorite Biomedical's stock price is NT$13.00. Vectorite Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$1.33. Therefore, Vectorite Biomedical's PS Ratio for today is 9.79.


Vectorite Biomedical EV-to-Revenue Historical Data

The historical data trend for Vectorite Biomedical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectorite Biomedical EV-to-Revenue Chart

Vectorite Biomedical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.05 - - 13.05 7.55

Vectorite Biomedical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 13.05 - 7.55

Competitive Comparison of Vectorite Biomedical's EV-to-Revenue

For the Biotechnology subindustry, Vectorite Biomedical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectorite Biomedical's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vectorite Biomedical's EV-to-Revenue falls into.


;
;

Vectorite Biomedical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vectorite Biomedical's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=384.540/57.77
=6.66

Vectorite Biomedical's current Enterprise Value is NT$384.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectorite Biomedical's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$57.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectorite Biomedical  (ROCO:4170) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vectorite Biomedical's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=13.00/1.328
=9.79

Vectorite Biomedical's share price for today is NT$13.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was NT$1.33.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectorite Biomedical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vectorite Biomedical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectorite Biomedical Business Description

Traded in Other Exchanges
N/A
Address
Number 97, Section 1, Xintai 5th Road, 6th Floor, Floor-11, Yuzhi District, New Taipei City, Taipei, TWN, 22175
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.

Vectorite Biomedical Headlines

No Headlines